Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
One or more suppliers on this contract have also made political donations. See supplier details below.
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
Offer reference number: CM/PHS/25/5728
Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months.
Potential periods of call-offs under the framework agreement:
CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments:
7NAT (National) 01/12/2025 to 31/05/2027 (18 months)
CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments aflibercept 2mg:
NOFE: (North of England) 01/12/2025 to 31/05/2027 (18 months)
SOFE: (South of England) 01/12/2025 to 31/05/2027 (18 months)
MAE: (Midlands and East) 01/12/2025 to 31/05/2027 (18 months)
LNW: (London) 01/12/2025 to 31/05/2027 (18 months)
Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England
Provision of Licensed Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of;
| Supplier | Identifier | Award Value | Lots Won | Cross-References |
|---|---|---|---|---|
| ABBVIE LTD | 08004972 | £1,471,752,146 | 1 lot CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: | LOBBYIST Policy Connect Limited (15 quarters) Portland PR Limited (3 quarters) WA Communications Ltd (3 quarters) Incisive Health Ltd (1 quarter) Political Lobbying & Media Relations Limited (1 quarter) |
| ALIMERA SCIENCES LIMITED | 08018355 | £1,471,752,146 | 1 lot CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: | - |
| Bayer Plc | Procurement ID: PWRY-2527-LDRY | ~£1,492,447,130 estimated from lot values | 1 lot CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: | - |
| BAYER PUBLIC LIMITED COMPANY | 00935048 | £1,471,752,146 | 1 lot CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: | LOBBYIST Ovid Consulting Ltd (6 quarters) Hill & Knowlton Limited (2 quarters) Hanover Communications International Limited (1 quarter) iNHouse Communications Limited (1 quarter) |
| Biogen | 06151086 | £782,917,972 | 1 lot CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: | - |
| BIOGEN IDEC LIMITED | 01497267 | £688,834,174 | 1 lot CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: | LOBBYIST Portland PR Limited (2 quarters) Hawthorn Advisors Limited (1 quarter) |
| Biosimilar Collaborations Ireland Limited | Procurement ID: PQQC-5869-LMVX | £782,917,972 | 1 lot CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: | - |
| CELLTRION HEALTHCARE UNITED KINGDOM LIMITED | 11685363 | £782,917,972 | 1 lot CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: | - |
| MDBIOLOGICS LTD | 15579040 | £782,917,972 | 1 lot CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: | - |
| NOVARTIS PHARMACEUTICALS UK LIMITED | 00119006 | £1,471,752,146 | 1 lot CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: | DONOR£3K across 2 donations To: Mr Nicholas Palmer LOBBYIST M&F Health (7 quarters) Sovereign Strategy Limited (1 quarter) MP LINK Mr David Lammy— Employment and earnings |
| ORION PHARMA (UK) LIMITED | 02281057 | £1,471,752,146 | 1 lot CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: | LOBBYIST Rud Pedersen UK Limited (5 quarters) |
| Outlook Therapeutics, Inc. | 08179857 | £1,471,752,146 | 1 lot CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: | - |
| ROCHE PRODUCTS LIMITED | 00100674 | £1,471,752,146 | 1 lot CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: | LOBBYIST M&F Health (5 quarters) Ovid Consulting Ltd (2 quarters) |
| SANDOZ LIMITED | 01547204 | £782,917,972 | 1 lot CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: | - |
| TEVA UK LIMITED | 00302461 | £1,471,752,146 | 1 lot CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: | - |
| Thornton and Ross Ltd | 00185947 | £782,917,972 | 1 lot CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: | - |
| THORNTON & ROSS LIMITED | 00185947 | £688,834,174 | 1 lot CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: | - |
This procurement was divided into 2 lots, each awarded separately. 18 bids were received in total.
| Lot | Value | Bids Received | Awarded To | Status |
|---|---|---|---|---|
| Lot 1 CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: Dec 2025 – May 2027 | £709,529,158 £1,471,752,146 initial term | 11 | Biosimilar Collaborations Ireland Limited Abbvie Ltd Alimera Sciences Biogen Novartis Pharmaceuticals UK Ltd Orion Pharma (UK) Ltd Roche Products Ltd Teva UK Limited Thornton and Ross Ltd BIOSIMILAR COLLABORATIONS IRELAND LIMITED Celltrion Healthcare United Kingdom Limited | active |
| Lot 2 CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments a Dec 2025 – May 2027 | £810,903,137 | 7 | - | complete |
Notices published under the Procurement Act 2023 name every bidder, including unsuccessful ones.
| Bidder | Bid on | Outcome |
|---|---|---|
| ABBVIE LTD | Lot 1 | Wonlot 1 |
| ALIMERA SCIENCES LIMITED | Lot 1 | Wonlot 1 |
| BAYER PUBLIC LIMITED COMPANY | Lots 1, 2 | Wonlot 1 |
| BIOGEN IDEC LIMITED | Lot 1 | Wonlot 1 |
| Biosimilar Collaborations Ireland Limited | Lot 2 | Wonlot 1 |
| CELLTRION HEALTHCARE UNITED KINGDOM LIMITED | Lot 2 | Wonlot 1 |
| MDBIOLOGICS LTD | Lot 2 | Wonlot 1 |
| NOVARTIS PHARMACEUTICALS UK LIMITED | Lot 1 | Wonlot 1 |
| ORION PHARMA (UK) LIMITED | Lot 1 | Wonlot 1 |
| Outlook Therapeutics, Inc. | Lot 1 | Wonlot 1 |
| ROCHE PRODUCTS LIMITED | Lot 1 | Wonlot 1 |
| SANDOZ LIMITED | Lot 2 | Wonlot 1 |
| TEVA UK LIMITED | Lot 1 | Wonlot 1 |
| THORNTON & ROSS LIMITED | Lot 1 | Wonlot 1 |
| AMGEN LIMITED | Lot 2 | Unsuccessful |
| MERCURY PHARMACEUTICALS LIMITED | Lot 2 | Unsuccessful |
| ORIFARM UK LTD | Lot 1 | Unsuccessful |
Weightings from the notice, applied to every lot.
Government spending data: These suppliers have received £547,293,477 in 6,694 payments (over £25k) from Manchester University NHS Foundation Trust, Department of Health and Social Care, NHS England, Guy's and St Thomas' NHS FT, East Sussex Healthcare NHS Trust and 18 more public bodies (2010-07-22 to 2026-03-31).
Changes the buyer published to this notice after it first appeared.
Adding in Tender documents to this notice.